secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001140361-23-024218
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 7.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion sells zagociguat & CY3018 for $8M cash + 10% equity; CEO to lead NewCo
--------------------------------------------------------------------------------

- Receives $8M cash at closing and 10% equity in NewCo with anti-dilution protection through $100M post-money.
- NewCo investors (Invus, Venrock, J Wood Capital, Sanofi Ventures) commit $81M to develop zagociguat and CY3018.
- CEO Peter Hecht will transition to NewCo as CEO; Errol De Souza elected Chair of Cyclerion Board.
- Signing triggers $5M equity investment by Hecht at $0.434/share; proceeds plus $8M expected to fund operations for 12+ mos.
- Q1 2023 cash $7.2M (down from $13.4M year-end 2022); company to seek later-stage CNS assets under new leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/0001140361-23-024218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000114036123024218/brhc20052804_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer